55 results
8-K
EX-99.1
XLO
Xilio Therapeutics Inc
14 May 24
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
7:45am
bispecific and immune cell engager programs
Xilio’s research-stage development efforts are focused on advancing a pipeline of tumor-activated bispecifics … and Gilead.
Research & Development (R&D) Expenses: R&D expenses were $10.4 million for the quarter ended March 31, 2024, compared to $16.1 million
8-K
EX-99.1
wdqu6wj17y8 12i0t
1 Apr 24
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
4:15pm
8-K
EX-99.2
yozg6ss m3xtiumeb
28 Mar 24
Entry into a Material Definitive Agreement
7:55am
8-K
EX-99.1
0dqxbtqxnp3g
28 Mar 24
Entry into a Material Definitive Agreement
7:55am
8-K
EX-99.1
t7w6f mdwcll6d013ksg
7 Dec 23
Other Events
7:45am
8-K
osj3mhtxg3idimxg
7 Dec 23
Other Events
7:45am
8-K
EX-99.1
nehf6usl
9 Nov 23
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
4:13pm
8-K
ge0egnt 08wm1y
3 Nov 23
Other Events
4:05pm
8-K
EX-99.1
gazg0rp ij
3 Nov 23
Other Events
4:05pm
8-K
5un0kyhsqqz0 6lg
5 Sep 23
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
8:35am
8-K
EX-99.1
tlggwv6621ca4hy9u
5 Sep 23
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
8:35am
8-K
EX-99.2
dfid1dc
14 Aug 23
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
7:40am